Literature DB >> 23576652

Visceral leishmaniasis with HIV co-infection and cervical lymphadenopathy.

Sanjay Mishra1, Ayush Shukla, Anil Kumar Tripathi, Ashutosh Kumar.   

Abstract

Visceral leishmaniasis (VL) is prevalent worldwide. In the past there has been steep rise in the incidence of VL in southern Europe and Africa. Factors attributed for this are economic development, a shift of the reservoir of Leishmania, immunodeficiency due to HIV infection and intravenous drug abuse. The co-infection of VL and HIV is common in southern European-African countries and is proposed that it should be included as an AIDS-defining illness. VL is not only considered to be an opportunistic infection in HIV-infected individuals but it may also reactivate latent infection. This case is worth reporting as it highlights increasing incidence of VL-HIV co-infection and its sparse literature from India, changing ecology and possible evolving epidemic in the Indian subcontinent. Additionally an atypical presentation such as lymphadenopathy in VL should arouse suspicion of HIV co-infection and vice versa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23576652      PMCID: PMC3645008          DOI: 10.1136/bcr-2012-008433

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

Review 1.  Global control and Leishmania HIV co-infection.

Authors:  P Desjeux
Journal:  Clin Dermatol       Date:  1999 May-Jun       Impact factor: 3.541

2.  Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India.

Authors:  C P Thakur; P K Sinha; R K Singh; S M Hassan; S Narain
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Nov-Dec       Impact factor: 2.184

3.  Visceral Leishmaniasis and HIV Coinfection in Bihar, India.

Authors:  Prabhat Kumar Sinha; Vidya Nand Rabidas; Krishna Pandey; Neena Verma; Anil Kumar Gupta; Alok Ranjan; Pradip Das; Sujit Kumar Bhattacharya
Journal:  J Acquir Immune Defic Syndr       Date:  2003-01-01       Impact factor: 3.731

Review 4.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

5.  Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics.

Authors:  Purva Mathur; J C Samantaray; Madhu Vajpayee; Palash Samanta
Journal:  J Med Microbiol       Date:  2006-07       Impact factor: 2.472

6.  Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.

Authors:  Prabhat K Sinha; Johan van Griensven; Krishna Pandey; Nawin Kumar; Neena Verma; Raman Mahajan; Pankaj Kumar; Ranjeet Kumar; Pradeeb Das; Gaurab Mitra; Laurence Flevaud; Cecilia Ferreyra; Daniel Remartinez; Manuel Pece; Pedro Pablo Palma
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.